Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptimmune Therapeutics PLCADAP · Entity 9824 | Director | July 01, 2024 | July 01, 2024 |
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director | June 26, 2026 | June 29, 2026 |
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director | June 03, 2025 | June 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptimmune Therapeutics PLC
Report date July 01, 2024 · Filed July 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.16 · Expires 2034-07-01 | Direct | 1,121,604 |
Reported balance
After 2024-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-01 · Grant · Acquired 1,121,604 · Balance 1,121,604 F1: The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount.
Black Diamond Therapeutics, Inc.
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2036-06-25 | Direct | 40,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Stoke Therapeutics, Inc.
Report date June 03, 2025 · Filed June 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.90 · Expires 2035-06-02 | Direct | 29,747 |
Reported balance
After 2025-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-03 · Grant · Acquired 29,747 · Balance 29,747 F1: The option shall vest in full on the earlier of: (i) June 3, 2026 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earlier of: (i) June 3, 2026 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TCR2 THERAPEUTICS INC.
Report date June 01, 2023 · Filed June 01, 2023
Section 16 reporting ended · disclosed 2023-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-06-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-06-01 · Disposition to issuer · Disposed 132,729 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F3: Consists of 132,729 Shares held by the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Menzel Trust"). The Reporting Person is the trustee of the Menzel Trust, and as such the Reporting Person may be deemed to beneficially own such securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Menzel Trust. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-06-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-06-01 · Disposition to issuer · Disposed 132,730 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F4: Consists of 132,730 Shares held by and the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The Reporting Person's spouse is the trustee of the Henshall Trust, and as such the Reporting Person may be deemed to beneficially own such securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Henshall Trust. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-06-01 transaction · row 3
1 source rowRow 3 · 2023-06-01 · Disposition to issuer · Disposed 138,871 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.74 | Direct | 0 |
Reported balance
After 2023-06-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-01 · Disposition to issuer · Disposed 138,031 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F5: Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.88 | Direct | 0 |
Reported balance
After 2023-06-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-06-01 · Disposition to issuer · Disposed 433,037 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F5: Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 | Direct | 0 |
Reported balance
After 2023-06-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-06-01 · Disposition to issuer · Disposed 305,800 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F5: Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 | Direct | 0 |
Reported balance
After 2023-06-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-06-01 · Disposition to issuer · Disposed 238,008 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F5: Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-06-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-06-01 · Disposition to issuer · Disposed 3,241 · Balance 0 F6: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans. F7: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-06-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-06-01 · Disposition to issuer · Disposed 15,120 · Balance 0 F6: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans. F7: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-06-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-06-01 · Disposition to issuer · Disposed 23,165 · Balance 0 F6: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans. F7: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-06-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-06-01 · Disposition to issuer · Disposed 39,681 · Balance 0 F6: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans. F7: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").
F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares").
F3: Consists of 132,729 Shares held by the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Menzel Trust"). The Reporting Person is the trustee of the Menzel Trust, and as such the Reporting Person may be deemed to beneficially own such securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Menzel Trust.
F4: Consists of 132,730 Shares held by and the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The Reporting Person's spouse is the trustee of the Henshall Trust, and as such the Reporting Person may be deemed to beneficially own such securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Henshall Trust.
F5: Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.
F6: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.
F7: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 17, 2022 Filed Nov 18, 2022 16:56 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Disposition to issuerStock Option (right to buy) · Derivative | 164,500 | $0.00 Strike: $16.10 | $0.00 |
DisclosureSEC source: 0000899243-22-036395 · doc4.xml · derivative · entry 9 Menzel Garry E · CIK 0001556064 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 164,500 shares Expires 2029-12-18 F11 · price: On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 54,834. F8 · derivative.exercise_date: This cancelled option vested 25% on January 1, 2021 and the remaining 75% vests in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 16:56 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantRestricted Stock Unit (right to buy) · Derivative | 1,167 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-036395 · doc4.xml · derivative · entry 8 Menzel Garry E · CIK 0001556064 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,167 Underlying: Common Stock · 1,167 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration. F9 · price: On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 1,167. F10 · derivative.exercise_date: 73% of these RSUs will vest on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024. F10 · derivative.expiration_date: 73% of these RSUs will vest on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 16:56 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Disposition to issuerStock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $16.10 | $0.00 |
DisclosureSEC source: 0000899243-22-036395 · doc4.xml · derivative · entry 7 Menzel Garry E · CIK 0001556064 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires 2029-12-18 F9 · price: On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 1,167. F8 · derivative.exercise_date: This cancelled option vested 25% on January 1, 2021 and the remaining 75% vests in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 16:56 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantRestricted Stock Unit (right to buy) · Derivative | 159,956 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-036395 · doc4.xml · derivative · entry 6 Menzel Garry E · CIK 0001556064 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,956 Underlying: Common Stock · 159,956 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration. F7 · price: On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on April 11, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 159,956. F6 · derivative.exercise_date: The restricted stock units will vest 98% on December 1, 2022, and 2% on December 1, 2023. F6 · derivative.expiration_date: The restricted stock units will vest 98% on December 1, 2022, and 2% on December 1, 2023. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 16:56 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Disposition to issuerStock Option (right to buy) · Derivative | 479,866 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0000899243-22-036395 · doc4.xml · derivative · entry 5 Menzel Garry E · CIK 0001556064 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 479,866 shares Expires 2029-04-10 F7 · price: On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on April 11, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 159,956. F3 · derivative.exercise_date: This cancelled option vested 25% on January 1, 2020 and the remaining 75% vests in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 16:56 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantRestricted Stock Unit (right to buy) · Derivative | 2,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-036395 · doc4.xml · derivative · entry 4 Menzel Garry E · CIK 0001556064 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,080 Underlying: Common Stock · 2,080 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration. F4 · price: On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on April 11, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 2,080. F6 · derivative.exercise_date: The restricted stock units will vest 98% on December 1, 2022, and 2% on December 1, 2023. F6 · derivative.expiration_date: The restricted stock units will vest 98% on December 1, 2022, and 2% on December 1, 2023. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 16:56 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Disposition to issuerStock Option (right to buy) · Derivative | 6,240 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0000899243-22-036395 · doc4.xml · derivative · entry 3 Menzel Garry E · CIK 0001556064 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,240 shares Expires 2029-04-10 F4 · price: On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on April 11, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 2,080. F3 · derivative.exercise_date: This cancelled option vested 25% on January 1, 2020 and the remaining 75% vests in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 05, 2022 Filed Aug 26, 2022 16:30 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GiftCommon Stock | 132,730 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-029864 · doc4.xml · nonDerivative · entry 6 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 132,730 F3 · balance_after: The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 132,730 shares of common stock held by the reporting person to the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust. F3 · ownership.nature: The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 132,730 shares of common stock held by the reporting person to the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust. Read SEC document |
| July 05, 2022 Filed Aug 26, 2022 16:30 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GiftCommon Stock | 132,730 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-029864 · doc4.xml · nonDerivative · entry 5 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · balance_after: The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 132,730 shares of common stock held by the reporting person to the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust. F3 · ownership.direct: The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 132,730 shares of common stock held by the reporting person to the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust. Read SEC document |
| July 05, 2022 Filed Aug 26, 2022 16:30 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GiftCommon Stock | 48,202 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-029864 · doc4.xml · nonDerivative · entry 4 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 132,729 F2 · balance_after: The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 48,202 shares of common stock held by the reporting person to the Menzel Trust. F2 · ownership.nature: The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 48,202 shares of common stock held by the reporting person to the Menzel Trust. Read SEC document |
| July 05, 2022 Filed Aug 26, 2022 16:30 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GiftCommon Stock | 48,202 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-029864 · doc4.xml · nonDerivative · entry 3 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,730 F2 · balance_after: The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 48,202 shares of common stock held by the reporting person to the Menzel Trust. F2 · ownership.direct: The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 48,202 shares of common stock held by the reporting person to the Menzel Trust. Read SEC document |
| July 05, 2022 Filed Aug 26, 2022 16:30 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GiftCommon Stock | 84,527 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-029864 · doc4.xml · nonDerivative · entry 2 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 84,527 F1 · shares: The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 84,527 shares of common stock held by the reporting person, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010, to the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 45, 2022 (the "Menzel Trust"). The reporting person is the trustee of the Menzel Trust and may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust. F1 · balance_after: The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 84,527 shares of common stock held by the reporting person, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010, to the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 45, 2022 (the "Menzel Trust"). The reporting person is the trustee of the Menzel Trust and may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust. F1 · ownership.nature: The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 84,527 shares of common stock held by the reporting person, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010, to the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 45, 2022 (the "Menzel Trust"). The reporting person is the trustee of the Menzel Trust and may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust. Read SEC document |
| July 05, 2022 Filed Aug 26, 2022 16:30 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GiftCommon Stock | 84,527 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-029864 · doc4.xml · nonDerivative · entry 1 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · balance_after: The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 84,527 shares of common stock held by the reporting person, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010, to the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 45, 2022 (the "Menzel Trust"). The reporting person is the trustee of the Menzel Trust and may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust. F1 · ownership.nature: The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 84,527 shares of common stock held by the reporting person, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010, to the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 45, 2022 (the "Menzel Trust"). The reporting person is the trustee of the Menzel Trust and may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:04 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-006516 · form4-06132022_040607.xml · derivative · entry 1 Menzel Garry E · CIK 0001556064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 21:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001209191-22-035079 · doc4.xml · derivative · entry 1 Menzel Garry E · CIK 0001556064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: The option shall vest on June 7, 2023 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| February 28, 2022 Filed Mar 18, 2022 16:24 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantCommon Stock | 1,425 | $2.30 | $3,277.50 |
DisclosureSEC source: 0001209191-22-020025 · doc4.xml · nonDerivative · entry 2 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,932 F2 · kind: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of September 1, 2021 through February 28, 2022. This transaction is exempt under Rule 16b-3(c). F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 28, 2022. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 16:32 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,946 | $0.74 Strike: $0.74 | $4,400.04 |
DisclosureSEC source: 0001209191-21-069050 · doc4.xml · derivative · entry 5 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,031 Underlying: Common Stock · 5,946 shares Expires 2027-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of this option vested and became exercisable on December 6, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 16:32 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionStock Option (Right to Buy) · Derivative | 169,054 | $0.74 Strike: $0.74 | $125,099.96 |
DisclosureSEC source: 0001209191-21-069050 · doc4.xml · derivative · entry 4 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 169,054 shares Expires 2026-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted an option to purchase 253,581 shares on December 13, 2016. 84,527 of such options were previously exercised. 25% of this option vested and became exercisable on October 17, 2017, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 16:32 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantStock Option (Right to Buy) · Derivative | 305,800 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001209191-21-069050 · doc4.xml · derivative · entry 6 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,800 Underlying: Common Stock · 305,800 shares Expires 2031-12-08 F6 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 16:32 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionCommon Stock | 175,000 | $0.74 | $129,500.00 |
DisclosureSEC source: 0001209191-21-069050 · doc4.xml · nonDerivative · entry 3 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2021 Filed Dec 10, 2021 16:32 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantCommon Stock | 422 | $14.26 | $6,017.72 |
DisclosureSEC source: 0001209191-21-069050 · doc4.xml · nonDerivative · entry 2 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,507 F2 · kind: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of March 1, 2021 through August 31, 2021. This transaction is exempt under Rule 16b-3(c). F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on August 31, 2021. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:15 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001104659-21-084245 · tm2120371-5_4seq1.xml · derivative · entry 1 Menzel Garry E · CIK 0001556064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 08, 2021 Filed Jun 25, 2021 21:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 11,650 | $0.00 Strike: $40.37 | $0.00 |
DisclosureSEC source: 0001209191-21-043335 · doc4.xml · derivative · entry 1 Menzel Garry E · CIK 0001556064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,650 Underlying: Common Stock · 11,650 shares Expires 2031-06-07 F1 · derivative.exercise_date: The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| April 20, 2021 Filed Apr 24, 2021 01:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 14,921 | $0.00 Strike: $24.33 | $0.00 |
DisclosureSEC source: 0001104659-21-054611 · tm2113912-2_4seq1.xml · derivative · entry 1 Menzel Garry E · CIK 0001556064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,921 Underlying: Common Stock · 14,921 shares Expires 2031-04-19 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2021 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| February 28, 2021 Filed Mar 8, 2021 08:16 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantCommon Stock | 686 | $16.12 | $11,061.41 |
DisclosureSEC source: 0000899243-21-010266 · doc4.xml · nonDerivative · entry 3 Menzel Garry E · CIK 0001556064 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,085 F4 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the ESPP for the ESPP purchase period of September 1, 2020 through February 28, 2021. This transaction is exempt under Rule 16b-3(c). F5 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on September 1, 2020. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 06:17 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantStock Option (Right to Buy) · Derivative | 245,000 | $0.00 Strike: $31.38 | $0.00 |
DisclosureSEC source: 0000899243-20-033476 · doc4.xml · derivative · entry 3 Menzel Garry E · CIK 0001556064 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 Underlying: Common Stock · 245,000 shares Expires 2030-12-09 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| August 31, 2020 Filed Mar 8, 2021 08:16 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantCommon Stock | 1,132 | $10.10 | $11,430.94 |
DisclosureSEC source: 0000899243-21-010266 · doc4.xml · nonDerivative · entry 2 Menzel Garry E · CIK 0001556064 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,399 F2 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of March 1, 2020 through August 31, 2020. This transaction is exempt under Rule 16b-3(c). F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 28, 2020. Read SEC document |
| August 13, 2020 Filed Jan 27, 2021 22:19 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 29,555 | $0.00 Strike: $28.57 | $0.00 |
DisclosureSEC source: 0001209191-21-005724 · doc4.xml · derivative · entry 1 Menzel Garry E · CIK 0001556064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,555 Underlying: Common Stock · 29,555 shares Expires 2030-08-13 F1 · derivative.exercise_date: The option vested as to 1/12th of the total shares on November 13, 2020, and then 1/12th of the total shares vest quarterly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 28, 2020 Filed Mar 27, 2020 16:15 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantCommon Stock | 1,287 | $10.10 | $12,998.70 |
DisclosureSEC source: 0001209191-20-021382 · doc4.xml · nonDerivative · entry 3 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,267 F4 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the ESPP for the ESPP purchase period of September 2, 2019 through February 28, 2020. This transaction is exempt under Rule 16b-3(c). F5 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 28, 2020. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:56 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries A Preferred Stock · Derivative | 156,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003357 · doc4.xml · derivative · entry 2 Menzel Garry E · CIK 0001556064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 51,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by Dr. Garry Menzel, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust. Dr. Menzel is the trustee of the Garry E. Menzel and Mary E. Henshall Family Trust and may be deemed to beneficially own these securities. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:56 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 51,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003357 · doc4.xml · nonDerivative · entry 1 Menzel Garry E · CIK 0001556064 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 51,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by Dr. Garry Menzel, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust. Dr. Menzel is the trustee of the Garry E. Menzel and Mary E. Henshall Family Trust and may be deemed to beneficially own these securities. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 19:45 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantStock Option (Right to Buy) · Derivative | 168,000 | $0.00 Strike: $16.10 | $0.00 |
DisclosureSEC source: 0000899243-19-029860 · doc4.xml · derivative · entry 2 Menzel Garry E · CIK 0001556064 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,000 Underlying: Common Stock · 168,000 shares Expires 2029-12-18 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2021, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| August 30, 2019 Filed Mar 27, 2020 16:15 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantCommon Stock | 980 | $12.75 | $12,495.00 |
DisclosureSEC source: 0001209191-20-021382 · doc4.xml · nonDerivative · entry 2 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 980 F2 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of February 13, 2019 through August 30, 2019. This transaction is exempt under Rule 16b-3(c). F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 13, 2019. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 16:07 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantStock Option (Right to Buy) · Derivative | 486,106 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0001750019-19-000023 · wf-form4_155509964116859.xml · derivative · entry 1 Menzel Garry E · CIK 0001556064 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,106 Underlying: Common Stock · 486,106 shares Expires 2029-04-10 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.